# Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.

> **NCT00531115** · PHASE2 · TERMINATED · sponsor: **Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)** · enrollment: 28 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** cetuximab 5mg/ml

## Key facts

- **NCT ID:** NCT00531115
- **Lead sponsor:** Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** According to the study design, in the first step the number of responses was lower than the number required (\< 7).
- **Last updated:** 2013-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531115, "Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00531115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*